San Diego-based Celladon Corp. has revived the initial public offering it postponed last November.

The company previously planned to raise $75 million in an IPO scheduled November 14, 2013, but postponed it due to unfavorable market conditions. Celladon removed the original IPO terms in an updated S-1 filing with the Securities and Exchange Commission.

The company, which is developing therapies for heart failure, plans to trade on the Nasdaq under ticker symbol CLDN.